Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that it has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version of Prometrium® (Progesterone) Capsules in the United States market, approved by the U.S. Food and Drug Administration (USFDA).
The Prometrium® brand and generic had U.S. sales of approximately $153 million MAT for the most recent twelve months ending in February 2017 according to IMS Health*.
Dr. Reddy’s Progesterone Capsules, 100 mg and 200 mg, are available in bottle count size of 100.
Prometrium® is a registered trademark of ABBVIE Products LLC.
